chevron_leftBack
As of 13 June 2026, Context Therapeutics Inc. has a market cap of $215.46M USD, ranking #20591 globally and #3374 in the United States.
It ranks #1849 in the Healthcare sector, and #673 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$215.46MUSD
Enterprise Value
$149.11MUSD
EBITDA (TTM)
-$39.69MUSD
Net Income (TTM)
-$36.12MUSD
PB Ratio
3.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Martin Lehr
open_in_new
Employees
15
Founded
2015
IPO
20 Oct 2021
Website
contexttherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.6% | -2.7% | -9.5% | -2.3% | 100% | 149% |
News
Loading...
CNTX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CNTX
Context Therapeutics Inc
ISIN: US21077P1084
Shares Out.:
Shares Outstanding:
91.879M1
Shares Float:
82.757M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.35 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
353K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
254K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
167K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
127K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
69K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
54K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
149K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
134K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
127K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
84K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
51K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
50K%
80.96B GBP
|
14.6
|
chevron_leftBack